Skip to main content
. 2023 Oct 20;299(12):105369. doi: 10.1016/j.jbc.2023.105369

Figure 3.

Figure 3

Actin-cMyBPC FLT-FRET assay.A, FLT-FRET-based binding curve of 0.25 μM FMAL-actin and 0 to 20 μM TMR-cC0-C2 (solid black line, unphosphorylated), PKA-phosphorylated (#P) TMR-cC0-C2 (dashed black line) and TMR-fC1-C2 (solid blue line). Phosphorylation of cC0-C2 decreases its binding to actin. B, expansion of 0 to 5 μM of (A). The concentration of TMR-cC0-C2 and TMR-fC1-C2 (0.5 μM) and phosphorylated TMR-cC0-C2 (1 μM) used in the HTS screen and in testing of compound effects is indicated with arrows. Data are mean ± SD. n = 7 to 10 from N = 2 separate actin and cC0-C2 or fC1-C2 preparations. All values are the average ± SD.